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a b s t r a c t
The Ugandan national control programme for schistosomiasis has no clear policy for inclu-
sion of preschool-children (≤5 years old) children. To re-balance this health inequality, we
sought to identify best diagnosis of intestinal schistosomiasis, observe treatment safety
and efﬁcacy of praziquantel (PZQ), and extend the current WHO dose pole for chemother-
apy. We examined and treated 363 preschool children from shoreline villages of Lakes
Albert and Victoria, and found that 62·3% (CI95 57·1–67·3) of the children were conﬁrmed
to have intestinal schistosomiasis. One day after treatment, children were reported as hav-
ing headaches (3·6%), vomiting (9·4%), diarrhoea (10·9%) and urticaria/rash (8·9%) with
amelioration at 21-day follow-up, where the parasitological cure rate was found to be
100·0%. Height and weight data were collected from a further 3303 preschool children
to establish and validate an extended PZQ dose pole that now includes two new height-
intervals: 60–84 cm for one-half tablet and 84–99 cm for three-quarter tablet divisions;
which would result in 97·6% of children receiving an acceptable dose (30–60mg/kg). To
conclude, preschool children in lakeshore communities of Uganda are at signiﬁcant risk of
intestinal schistosomiasis; we now strongly advocate for their immediate inclusion within
l progr
t © 20the national contro
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. IntroductionSchistosomiasis is considered a neglected tropical
isease (NTD) and affects around 200 million people
orldwide, many of whom develop severe and perma-
ent disabilities.1,2 Control of the infection has gained
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much international interest and political commitment
since 2000,when theUnitedNationsmember states and 23
international organizationsagreedon theeightMillennium
Development Goals (MDGs). The World Health Organiza-
tion (WHO)subsequently advocated that control of schisto-
somiasis contributes to the achievement of the MDGs, and
in 2001 the World Health Assembly endorsed resolution
54·19 which recommends regular de-worming of school-
aged children at risk of infection (http://www.who.int/inf-
pr-2001/en/pr2001WHA-6.html).3-5In the ﬁght against
al Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
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these diseases of poverty, preventive chemotherapy cam-
paigns are now the front-line intervention, administering
safe, efﬁcacious and low-cost anthelminthics, i.e. prazi-
quantel (PZQ) for schistosomiasis andalbendazole (ALB) for
soil-transmitted helminthiasis (STHs).6 In the past decade,
several campaigns have been implemented throughout
sub-Saharan Africa targeting school children (six to 15
years old) and/or adults (over 15 years old) in high-risk
occupational groups (e.g. ﬁshermen).7,8 Since 2003, more
than nine million school-aged children have been treated
for schistosomiasis in Uganda, and yet, as an unforeseen
consequence of current guidelines, young children (≤ six
years old) have been consistently overlooked.8,9 For exam-
ple, only recently has WHO policy categorised PZQ as a safe
drug for children as young as four years of age, an age-
limit not yet reﬂected in the drug package insert of most
drug producers, even though historical and recent evi-
dence suggests that riskof infection starts evenearlier.10–18
Moreover, the current WHO dose pole for PZQ adminis-
tration is only applicable to children taller than 94 cm,
typically aged between four and ﬁve years, and the risk
of choking due to the size, shape and palatability of PZQ
tablets has dissuaded mass drug administration initiatives
to include smaller children in their targeted populations.19
Nevertheless, given theyoung child’s disease andenhanced
risk for developing morbidity in early childhood, this cur-
rent health inequity should not persist.14,20-22
Thus to develop better national policies within Uganda,
and with a view to reﬁning international guidelines, we
aimed to provide detailed evidence on occurrence of
intestinal schistosomiasis in very young children (≤ six
yearsof age), toobserve theefﬁcacyandsafetyofPZQ in this
age-class and extend the current dose pole to facilitate the
allocation of treatments within mass drug administration
initiatives.
2. Methods
2.1. Study areas and populations
Two targeted epidemiological surveys aimed at detect-
ing intestinal schistosomiasis in preschool children were
undertaken on separate occasions in areas highly endemic
for intestinal schistosomiasis.23 The ﬁrst survey took place
in July 2007 in the Lake Albert region (Buliisa District) and
examined 125 mothers and their 131 preschool children
(≤six years of age). The second survey was conducted in
January/February 2009 in the Lake Victoria region (Mayuge
District) where 120 mothers and their 232 preschool chil-
dren were examined. Prior to enrolment, village-wide
community sensitisation to the study’s objectives was
conducted by liaison with local health workers. Families
were then recruited foremost upon preliminary informed
assent and availability to attend the two-day walk-in
survey clinic to maximise provision of duplicate fae-
cal samples, enhancing the opportunity for more precise
detection of infections. The lake systems and eight study
villages of Tonya, Runga, Walukuba and Bugoigo (along
Lake Albert shoreline) and Walumbe, Nakalanga, Nakirim-
ira and Kayanja (along Lake Victoria shoreline) are shown
in Figure 1.nal Health 2 (2010) 103–113
2.2. Case-history questionnaires
As young children were to be examined it was essential
to include each child’s mother for assistance in provision of
stool and urine samples from her child. Each mother was
also asked directly, or on behalf of her child, 27 questions
(in Lake Albert) or 24 (in Lake Victoria) recording: demo-
graphic information, general socio-economic indicators,
access to health care, general self-reported health condi-
tions andother variables (e.g.water contact behaviours and
access to medications). Upon the basis of preliminary anal-
ysis, three questions used in LakeAlbertwere subsequently
deemed superﬂuous and therefore omitted from the Lake
Victoria survey. Copies of the case-history questionnaires
are available upon request from the corresponding author.
2.3. Detection of schistosomiasis
Parasitological diagnosis of Schistosoma mansoni was
performed using two consecutive day stool samples and
double Kato-Katz (KK) smears prepared for each child and
mother.24 Results were expressed as eggs per gram of
faeces (epg) and infection intensities of S. mansoni were
categorised as follows: 1–100 epg as light, 101–400 epg
as medium and >400 epg as heavy infections. Finger-
prick blood (∼50l) was taken from mother and child to
obtain serum to ascertain schistosomiasis status using a
commercially available soluble egg antigen enzyme-linked
immunosorbent assay (SEA-ELISA; IVD Research Inc., Cals-
bad, USA).25 A single urine sample, taken fromeachmother
and child, provided a 50l aliquot for testing of the pres-
ence of schistosome circulating cathodic antigen (CCA)
with a commercially available immuno-chromatographic
dipstick (Rapid Medical Diagnostics, Pretoria, RSA), a rapid
diagnostic test for intestinal schistosomiasis.26
2.4. Efﬁcacy of treatment with PZQ and side-effects
Irrespective of infection status and to mimic mass drug
administration conditions during the investigative epi-
demiological surveys, all mothers and children received
standard doses of PZQ (CIPLA, Mumbai, India) calculated
by weight. In addition ALB (GSK, Uxbridge, UK) was
provided.18 For younger/smaller children (<2 year olds),
the PZQ tablets were crushed and mixed with orange juice
and sugar before administration (spoon-feeding), with the
help of themother, alongwith a chewable orangeﬂavoured
half-tablet of ALB.
Efﬁcacy of PZQ upon intestinal schistosomiasis was
assessed 21 days after treatment with a follow-up visit
using parasite detection methods as described above. For
logistical limitations, this section of the survey was only
conducted in the four villages of Lake Victoria. Two dif-
ferent cure rates (CR: the percentage of the infected
population negative for infection after drug treatment)
were calculated, the ﬁrst using data from microscopy
visualising egg-patent infections and second using urine
CCA-dipsticks. Egg reduction rate (ERR: the percentage
reduction in egg intensity as measured by faecal epg after
drug treatment) was calculated.27
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Figure 1. Schematic map of Uganda, with its major water bodies (in grey). Inset are a map of Africa (top left: Uganda is highlighted) as well as detailed
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caps of the study areas in Lake Albert (top right) and Victoria (bottom rig
nd children (nC) from different villages. The area of the dark sector in th
efer to Table 1 for prevalence values and CI95.
As part of a large-scale de-worming exercise in Bugoigo
nd Walukuba villages (Lake Albert), a follow-up of 1122
reschool children was performed 24h after treatment,
here mothers were asked to report whether their chil-
ren needed any medical assistance or had experienced
ny of the following symptoms since treatment: dizzi-
ess, headache, sleepiness, fatigue, vertigo, abdominal
ain, cramps, nausea, vomiting, diarrhoea, bloody stools,
ower back pain and urticaria/rash. Due to this exercise,
more formalised approach was taken in Lake Victo-
ia (193 children) to assess putative side-effects to PZQ.
nce again, mothers responded on behalf of their children
s to whether their child experienced any of the stated
ymptomsprior to treatment, at 24hours and21daysafter-
reatment. Any symptom putatively associated with PZQ
reatment was assessed by adjusting follow-up levels to
re-treatment levels.
.5. PZQ dose poleDuring the two mass treatment exercises undertaken in
onjunction with the epidemiological surveys, height and
eightmeasurementswere collected from2093 preschool
hildren (1144 children from Lake Albert and 949 chil-icting the prevalence of intestinal schistosomiasis in both mothers (nM)
rt is proportional to the prevalence of positives for egg-patent infection.
dren from Lake Victoria). Randomly selected data points
from Lake Albert (n=572) and Lake Victoria (n=474) were
compiled and used to establish a correlation between
height and weight of preschool children.28,29 From this
correlation, two new height thresholds were established,
corresponding to one-half and three-quarters of one
600mg tablet of PZQ, and the current threshold for one
tablet of PZQ on the WHO dose pole was amended.19 The
extended dose pole was then theoretically tested in three
phases: ﬁrstly, on the remaining data from the same cross-
sectional survey (572 children from Lake Albert and 475
children from Lake Victoria) to assess its applicability on
an equivalent population; secondly, on data from a differ-
ent Ugandan population surveyed between April and July
2009 in the same districts but from different villages (573
children from Lake Albert and 637 children from Lake Vic-
toria); and thirdly, on data from 470 Zanzibari preschool
children to assess the new dose pole’s applicability in
another schistosomiasis-endemic country.13 On all occa-
sions, height and weight measurements were performed
to precisions of 0·1 cm and 0·1kg, respectively. A safe and
efﬁcacious (i.e. acceptable) dose of PZQ was deﬁned as
being between 30–60mg/kg, and an optimal dose as being
between 40–60mg/kg.19
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2.6. Statistical analysis
Data were collected from each individual using pro-
forma data sheets, which were then entered using
EpiDataTM (The EpiData Association, Odense, Denmark)
and Microsoft Excel® spreadsheet software. The data thus
collated were analysed using the R statistical package® v
2·8·1 (The R Foundation for Statistical Computing, Vienna,
Austria).30 For prevalence values, 95% conﬁdence intervals
(CI95) were estimated using the exact method.31 Preva-
lence comparisons were performed using (one-tailed)
Fisher’s exact modiﬁcation of the 2×2 chi-squared test.32
For infection intensity values, the geometric mean of
Williams, GMW, was chosen as the measure of central ten-
dency due to the typical over-dispersion present in this
type of data, and CI95 values for GMW were estimated
according to Kirkwood and Stern.33,34
Univariate logistic regression was carried out to
ascertain risk factors associated with intestinal schisto-
somiasis in children and their mothers. Within village
intra-correlation in the data was accounted for using a
generalized linear mixed model with multivariate nor-
mal random effects (the random-effects of village in our
case), with penalized quasi-likelihood (function glmmPQL
inR).35 For each variable, odds ratio (OR) and P-valueswere
calculated, and a P-value <0·05 was considered indicative
of statistical signiﬁcance.
2.7. Ethical approval, informed consents
The Ugandan National Council of Science and Tech-
nology and the London School of Hygiene and Tropical
Medicine, UK, granted ethical approvals for these stud-
ies (application nos. LSHTM 06·45 and LSHTM 5538·09).
All mothers were sensitized by community leaders (Local
Chairman, level 1), community drug distributors or a dis-
trict Ministry of Health ofﬁcer to the nature of the survey
prior to the study. On the day of the study, mothers gave
informed consent by signing (or ﬁngerprinting) a consent
sheet.
3. Results
3.1. Epidemiological surveys: basic demographics
The mean age of children surveyed in Lakes Albert and
Victoria was 3·16 years (median of three years, range of
nine months to six years) and 3·02 years (median of three
years, range of four months to six years), with female to
male ratios of 0·64 and 1·11, respectively. The families who
participated in our studieswere of low socio-economic sta-
tus (more than 90% of mothers were housewives, farmers
or ﬁsherwomen) and 85% used the lake as the main source
ofwater. In bothpopulations, history of previous PZQ treat-
ment was 57·4% in mothers and 6·7% in their children.3.2. Detection of intestinal schistosomiasis
The prevalence of egg-patent intestinal schistosomia-
sis was 44·3% in children from Lake Albert [GMW =5·721
(CI95 5·312–6·130) epg] and 16·0% in children from Lakenal Health 2 (2010) 103–113
Victoria [GMW =0·795 (CI95 0·603–0·986) epg],with preva-
lence of heavy intensity S. mansoni infections signiﬁcantly
higher in children fromLakeAlbert (8·4%v. 1·3%,P<0·0001;
Table 1). When considering results pooled from positive
criteria on all diagnostic techniques for intestinal schisto-
somiasis (microscopy, CCA and SEA-ELISA), prevalence of
infectionwas 68·7% for children in LakeAlbert, and58·6% in
Lake Victoria. Importantly, the youngest case of egg-patent
schistosomiasis was a girl from Lake Victoria (six months
of age), while the youngest heavy intensity case (>400 epg)
was a boy from Lake Albert (nine months of age). Addition-
ally, positive cases by CCA commenced at six months of
age in Lake Victoria and nine months of age in Lake Albert,
while the ﬁrst SEA-ELISA positive children were one year
of age in both places.
The observed intestinal schistosomiasis prevalence
according to different techniques, and combinations
thereof, are summarised in Figure 2. Diagnosing intesti-
nal schistosomiasis by performing KK smears on two day’s
stool samples rather than on single stool sample led to a
small increase in the prevalence of infection in Lake Albert,
and a greater increase in the prevalence of infection in Lake
Victoria. CCA as a single diagnostic tool, and compared to
KK smears on two day’s stool samples, led to small dif-
ference in prevalence of S. mansoni in families from Lake
Albert [mothers (M): from 60·0% to 54·6%; children (C):
from 44·3% to 44·1%], while its application in Lake Vic-
toria led to a large increase in the number of individuals
considered S. mansoni-positive (M: from 29·2% to 39·2%;
C: from 16·0% to 52·3%). The use of CCA in conjunction
with KK smears from two days stool samples increased the
number of S. mansoni infections diagnosed, particularly in
Lake Victoria and with emphasis on children (M: +60%;
C: +229%). Similar trends were observed for SEA-ELISA.
Finally, by using all three methodologies (microscopy,
CCA and SEA-ELISA), the prevalence of infected mothers
rose by 37% in Lake Albert and 128% in Lake Victoria,
and the prevalence of infected children rose by 55% in
Lake Albert and 266% in Lake Victoria, when compared
to those recorded by using egg-positive criteria on KK
smears from two day’s stool samples as single diagnostic
method.
3.3. Risk factors associated with egg-patent intestinal
schistosomiasis
In shoreline villages of Lake Albert, even though preva-
lence of egg-patent intestinal schistosomiasis reached
38·1% in children under three years of age, children aged
between three and six yearswere at higher risk of infection
than their younger counterparts (OR=3·4; CI95 1·4–8·2;
P 0·007). Additionally, children taken to the lakeshore by
their mothers when fetching water were ﬁve times more
likely to be infected than those who are left at home (CI95
1·8–13·6; P 0·002). Children whose mothers were infected
with S.mansoni (egg-patent infection)were 5·5 timesmore
likely to be infected than those whose mothers were free
of infection (CI95 2·1–14·4; P<0·001). Children who spent
more time in the lakewaterweremore likely to be infected,
where every additional minute accounted for a 1% increase
in odds of infections (OR=1·01, CI95 1·003–1·014; P 0·003).
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Table 1
Prevalence (and CI95) of intestinal schistosomiasis in mothers and children from Lakes Albert and Victoria.
Lake Albert Lake Victoria
Prevalence in % (and CI95) of Mothers (n=125) Children (n=131) Mothers (n=120) Children (n=232)
Egg-positive intestinal schistosomiasisa 60·0 (50·8–68·7) 44·3 (35·6–53·2) 29·2 (21·2–38·2) 16·0 (11·5–21·3)
Light intensity (1–100epg) 33·6 (25·4–42·6) 24·4 (17·3–32·7) 21·7 (14·7–30·1) 12·1 (8·2–17·0)
Medium intensity (101–400epg) 14·4 (8·8–21·8) 11·5 (6·6–18·2) 4·2 (1·3–9·5) 2·6 (1·0–5·5)
8·
68
-Katz s
al SEA-E
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l
i
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F
(
iHeavy intensity (>400epg) 12·0 (6·9–19·0)
Intestinal schistosomiasisb 82·2 (74·5–88·4)
a Prevalence of egg-patent infections according to two-day double Kato
b Prevalence of egg-patent S. mansoni infection (Kato-Katz) and/or visu
hildren who spent between 30min and 1h daily in the
ake water were found to be 4·5 times more likely to be
nfected (CI95 1·5–13·2; P 0·008) than those who spent less
han 30min. Likewise, those who spent between 1h and
h, and those who spent more than 4h daily in the lake
aterwere 6·0 (CI95 2·0–17·7; P0·002) and11·6 times (CI95
igure 2. Charts detailing the different prevalence levels of intestinal schistosomia
≤6 year olds) and their mothers, from villages on the shores of Lakes Albert (top)
n dashed lines.4 (4·3–14·5) 3·3 (0·9–8·3) 1·3 (0·3–3·7)
·7 (60·0–76·5) 66·7 (57·5–75·0) 58·6 (52·0–65·0)
mears.
LISA positive reaction and/or CCA positives (≥trace).
1·1–124·8; P 0·046), respectively,more likely to be infected
than thosewho spent less than30min. Fromageographical
perspective, children from the northern villages of Bugoigo
and Walukuba were 4·6 times more likely to be infected
than those from the southern villages of Tonya and Runga
(CI95 2·0–10·2; P<0·001).
sis, assessed by different diagnosticmethodologies, in preschool children
and Victoria (bottom), Uganda. CI95 around the prevalence are indicated
ternatio108 J.C. Sousa-Figueiredo et al. / In
In shoreline villages of Lake Victoria, children aged
between three and six years were also at higher risk of
infection than their younger counterparts (OR=3·8; CI95
1·8–8·1; P<0·001), with a prevalence of egg-patent intesti-
nal schistosomiasis reaching 8·8% in children under three
years of age. Once again, children whose mothers were
infected with S. mansoni (egg-patent infection) were more
likely to be infected than those whose mothers were free
of infection (OR=2·3; CI95 1·1–4·8; P 0·035). Children who
spent more than 30min daily in the lake water were 2·5
times more likely to be infected than those who spent less
than 30min (CI95 1·1–5·6; P 0·024). Children who knew
how to swimwere 3·2more likely to be infected than those
who did not know (CI95 1·4–7·1; P 0·005). Children who
had a toilet available in or around their household were
less likely to be infected than those who did not (OR=0·5;
CI95 0·2–1·0; P 0·051).
3.4. Treatment efﬁcacy and side-effects
PZQ (standard dosage of 40mg/kg) had a CR of 100·0%
(28 children egg-patent at baseline; CI95 87·7–100·0%),
with the population prevalence (i.e. inclusive of children
who did not receive treatment) of S. mansoni egg-patent
infections decreasing signiﬁcantly (P<0·0001) from 16·0%
(CI95 11.5–21.3%) to 3·1% (CI95 1·1–6·6%) 21 days after
chemotherapy. According to data from CCA diagnosis,
PZQ had a CR of 65·1% (83 children positive at baseline;
CI9553·8–75·2%), with the population prevalence decreas-
ing signiﬁcantly (P<0·01) from 52·3% (CI95 45·4–59·2%) to
29·4% (CI95 22·9–36·7%) 21 days after chemotherapy. The
ERR for PZQ on S. mansoni infections was 100·0% (mean
infection intensity of those positive at baseline decreased
from 139·2 epg to 0·0 epg).
During mass administration of PZQ and ALB in Lake
Albert, side-effects directly related to tablet administra-
tion (e.g. choking or coughing) were very rare (prevalence
<0.1%) and not life-threatening. Twenty-four hours after
treatment in Lake Albert 2·6% of children (n=1122)
reported feeling ill, with abdominal pain (0·9%) and diar-
rhoea (0·8%) being the commonest symptoms. In Lake
Victoria, twenty-four hours after treatment all side-effects
investigated, with the exception of headache and lower-
back pain, were reported at varying prevalence levels,
Table 2
Percentage (%) of preschool children (≤6 years of age) to report symptoms 24hou
Note that background incidence of these symptoms (registered prior to treating
side-effects. Amelioration is deﬁned as the reduction in prevalence of symptoms
Symptoms 24hours later
Incidence % Amelioratio
Dizziness 10·6 7·4
Headache 1·8 47·9
Sleepiness 14·7 24·4
Fatigue 16·1 19·4
Vertigo 13·8 4·6
Abdominal pain 5·1 43·3
Cramps 11·3 39·2
Nausea 8·8 17·1
Vomiting 7·8 19·4
Lower back pain 0·5 5·1
Urticaria/rash 9·2 17·1nal Health 2 (2010) 103–113
from 5·1% of children complaining of abdominal pain to
16·1% reporting fatigue. Headache (3·6%), vomiting (9·4%),
diarrhoea (10·9%) and urticaria/rash (8·9%) were found at
signiﬁcant levels. By contrast, mothers reported very few
children (<1%) with any symptoms present on the day of
the 21-day follow-up. For full results see Table 2.
3.5. Treatment administration: description of the
extended PZQ dose pole
Using the equation for the relationship between height
and weight based on data from 1046 Ugandan chil-
dren (y=0·0029x2–0·2817x+14.526 in Figure 3A), height
thresholds were established corresponding to 7·5kg,
11·25kg and 15·0kg, the weights for one-half (300mg),
three-quarters (450mg) and one (600mg) PZQ tablet
administration, respectively. The resulting height thresh-
olds values were 60 cm, 84 cm and 99 cm, respectively. For
a representation of the current WHO dose pole and the
extended version, refer to Figure 4.
Using the equation for the relationship between height
and weight to predict the weight of children from the same
village, different villages within the same country and chil-
dren from another African country does not greatly affect
the percentage of those who would receive a safe and
efﬁcacious PZQ dosage (between 30 and 60mg/kg). The
mean dosage would vary between 40·5mg/kg for those
in the same village to 41·9mg/kg for those from a differ-
ent country. The dose pole estimated an optimal dosage in
61·4% (CI95 59·7–63·6%) and an acceptable dosage in 98·6%
(CI95 98·1–99·0%) for Ugandan children. For Zanzibari chil-
dren, the percentages of those that would receive optimal
and acceptable dosages were 69·6% (CI95 65·2–73·7%) and
97·6% (CI95 95·9–98·8%), respectively. Only 0·4%of the3303
Ugandan and 0·9% of the 470 Zanzibari children would
have received a sub-curative dosage, and 1·0% Ugandan
and 1·5% Zanzibari children would have received a slight
over-dosage (Table 3). Figure 3B shows the distribution
of dosages on all populations tested and depicts a normal
distribution around the target of 40mg/kg, albeit slightly
skewed to the right for Zanzibar indicating a slight ten-
dency to over-dose. Details of the results obtained in the
different data sets are presented in Table 3. Additionally,
the predicted dosage did not vary signiﬁcantly between
rs and 21 days after co-administration of albendazole and praziquantel.
) has been taken into account when calculating the incidence of actual
after chemotherapy.
21 days later
n % Incidence % Amelioration %
0·0 7·8
3·6 45·8
1·0 38·5
0·5 27·5
1·0 6·3
2·6 55·3
2·1 43·6
1·0 20·8
9·4 21·4
3·2 6·3
8·9 17·7
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Figure 3. Creating and applying the newly developed extended dose pole for the rapid administration of praziquantel to preschool children (≤six year olds). A Distribution of height and weight measurements
from Uganda (‘genesis’ population n=1046, ‘same villages’ population n=1047, ‘different villages’ population n=1210) and Zanzibar (n=470). A polynomial model was ﬁtted to indicate the correlation between
height and weight data from the ‘genesis’ population and then used to predict bodyweight of each subject from height. B The distribution of PZQ dosages that would have been given to Ugandan and Zanzibari
children if height had been used to predict weight. Vertical dotted lines mark the upper and lower ranges of dosage given in practise if the target dosage is 20, 40 or 60mg/kg.28 C and D Box-and-whisker plots
of theoretical dosages given to the different sexes and ages, respectively, using as test populations those from Uganda (‘different villages’ population) and Zanzibar (total n=1680). Shading depicts prevalence of
intestinal schistosomiasis at each age according to total diagnostic evidence from the two targeted surveys (see Figure 1), (total population: 18 children were under one, 46 were one, 67 were two, 81 were three,
69 were four, 36 were ﬁve and 17 were six years of age). The horizontal bar in the middle shows the median theoretical dosage; both boxes show the interquartile range (25th to 75th percentile); the vertical
dashed lines show the minimum and maximum values, or, the presence of outliers (the circles), show 1.5 times the interquartile range (roughly two times the standard deviation); the notches at the ‘waist’ give
an impression of CI95 around the medians, where boxes whose notches do not overlap have signiﬁcantly different medians (P<0·05).49
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Figure 4. Pictorial representation of the current WHO dose pole for
administration of PZQ tablets (at 600mg each) (left) and the proposed
dose pole (right) with two new height thresholds added to allow for
treatment of preschool children (≤six year olds): 60–84 cm for one-half
and 84–99 cm for three-quarters PZQ table.19 The illustrated child needs
three-quarters of one tablet. Additionally, the WHO pole’s single tablet
lower limit has been amended from 94cm to 99 cm.
Table 3
Performance of the extended dose pole in estimating PZQ dosages in preschool c
Figure 3A). A PZQ optimal dose was deﬁned as being between 40–60mg/kg and a
PZQ dose Uganda (n=1046) Uga
Dose administered (mg/kg)
Minimum 27·2 21·3
Maximum 84·4 89·5
Average (SDa) 40·8 (5·4) 40·5
No. (%) of individuals receiving dose (%)
<30 mg/kg 4 (0·4) 7 (0
≥30 & <40 mg/kg 399 (38·1) 409
≥40 & <50 mg/kg 577 (55·2) 587
≥50 to <60 mg/kg 49 (4·7) 32 (
>60 mg/kg 17 (1·6) 12 (
a SD= standard deviation.nal Health 2 (2010) 103–113
sexes (Figure 3C). As for different ages, the median dosage
given to infants (<1 year old) and children aged ﬁve years
would be slightly higher (P<0·05) than the dosage given
to children aged between two and four, albeit still within
the safe and efﬁcacious range (Figure 3C and 3D). Very
few individuals aged six years were included in the sur-
vey (15 of a total of 1680 children), explaining the wide
conﬁdence intervals around themediandosage. Prevalence
of intestinal schistosomiasis (according to microscopy,
rapid diagnostic test and/or serology) increases with age,
remaining above 40% at all times.
4. Discussion
In light of these targeted epidemiological surveys, we
have further demonstrated the occurrence of intestinal
schistosomiasis in preschool children from shoreline vil-
lages on two of the major lakes of East Africa. Given our
previous observations in Lake Victoria, we have revealed
the non-transient nature of this aspect of the disease
transmission.12 In so doing, we have made explicit the
necessity for mass treatment with PZQ for these children.
4.1. Intestinal schistosomiasis in young children
Across all surveyed villages, prevalence of egg-patent
infection in children was considerable, even more so if
we deﬁne an infected child as one diagnosed positively by
any of the diagnostic tools used–microscopy, CCA and SEA-
ELISA–with overall prevalence of 62.3% (CI95 57.1–67.3),
consistent with previous results for preschool children and
similar to that reported for school-aged children from the
same districts.12,17,23 Although egg-patent intestinal schis-
tosomiasis was present in very young children (youngest
aged six months), with heavy intensity infections observed
in children as young as nine months of age, children aged
between three and six years appeared to have raised inten-
sities of infection. This observation is likely representative
of the cumulative and increasing water contact behaviour
of the child, combined with the maturation and increasing
egg-laying capacity of schistosome worm pairs within the
child linked with advancing years. It should be noted, how-
ever, that mothers have an important role in inﬂuencing
their child’s infection status, particularly during the ﬁrst 24
months of life (i.e. likely when initial exposure(s) to water
hildren (≤6 year olds), from our different datasets (see Methods 2.5, and
n acceptable dose as being between 30–60mg/kg.19.
nda (n=1047) Uganda (n=1210) Zanzibar (n=470)
24·0 25·3
72·3 66·9
(5·5) 40·9 (4·4) 41·9 (5·7)
·7) 1 (0·1) 4 (0·9)
(39·1) 421 (34·8) 132 (28·1)
(56·1) 731 (60·4) 301 (64·0)
3·1) 52 (4·3) 26 (5·5)
1·1) 5 (0·4) 7 (1·5)
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ontaining schistosome cercariae commences), when the
hild is regularly taken to the lakeshore during household
hores and child-bathing.
These observations support a predominantly bimodal
roﬁle of exposure, from a spectrum of passive and active
rocesses, in this younger age-class, as suggested by
tothard and Gabrielli.14 For example, children aged three
nd below are much more dependent on their mother’s
ovements and child-bathing practices, so any contact
ith freshly drawn lake water is largely an involuntary,
r passive action of the child. By contrast, in slightly older
hildren, who have greater mobility and independence,
oluntary actions increase their water contact at lakeside
oints, whilst they are still vulnerable to any other ongoing
nvoluntary exposures.14
A heterogeneous distribution in parasite prevalence
as observed across lakeshore villages. In Lake Albert,
or example, the two northern villages–Bugoigo and
alukuba–had signiﬁcantly more intestinal schistosomia-
is than the southern villages, even though they were only
eparated by 15–30km of lakeshore (refer to Figure 1).
plausible explanation for this focality, typical of schis-
osomiasis, is differing abundance of snail hosts in the
outhern villages which were located on shorelines with
redominately more wave exposure. Freshwater snails of
he genus Biomphalaria are very sensitive to local aquatic
nvironments and only certain locations on the lakeshore
rovide the optimal conditions.36,37 Furthermore, on both
akeshores there was a household, or familial, aggregation
f intestinal schistosomiasis indicating disease focality or
patchiness’ even within a single village. Those households
ith heightened levels of exposure, and thus more vulner-
ble to infection, are likely located close to niches highly
nfested with the snail hosts.
With preschool children and infants typically account-
ng for the widest age-bracket on the population pyramid
f low and medium income countries, the numbers of
hose at risk of neglected tropical diseases in the ‘bottom
illion’ is signiﬁcantly increased.38 Importantly, the sig-
iﬁcance of schistosomiasis in such young children may
e presently underestimated, as synergisms with concur-
ent infections (e.g. malaria), or predisposition towards
xposure and infection of others (e.g. HIV), are still to be
etermined and may start much earlier in life than previ-
usly thought. 39,40
.2. Diagnosing intestinal schistosomiasis in preschool
hildren
Given the heterogeneity of the epidemiological land-
cape of Uganda, a future challenge for mass treatment
ampaigns is to ensure that PZQ is administered in themost
ost-effective and evidence-based way. Thus before mass
rug administration takes place, some attention should
e given to the rapid identiﬁcation of those communities
here intestinal schistosomiasis in preschool children is
ommon. From our current perspective, it can be safely
ssumed that mass treatment is urgently needed in vil-
ages on the immediate shorelines of these lakes without
dditional surveying, but moving inland and farther away
rom the lake, or outside these areas, there is a need fornal Health 2 (2010) 103–113 111
rapid assessmentmethods. Fromour experiences, themost
favourable diagnostic technique for S. mansoni appears
the CCA urine-dipstick, given the evidence of the test’s
satisfactory performance in school-aged children, its cost-
effectiveness (cost: £1·60; diagnosis time: 20min), ability
to detect non-egg-patent infections and ease of use by
staff with minimal training.26 On the other hand, even at
£1·60, CCA remains comparativelymore expensive thanKK
smear examination, which performed reasonably well in
high prevalence/infection intensity scenarios, such as the
Lake Albert shoreline. Given that stool microscopy is rou-
tinely conducted in Uganda, we suggest that KK smears
from a single stool sample, followed by statistical scaling,
is an appropriate technology to make a pragmatic esti-
mate of the local prevalence of intestinal schistosomiasis
in preschool children.
Although CCA and SEA-ELISA, as single diagnostic tools,
tended to identify increased numbers of children positive
for S. mansoni compared to double-sample KK smears at
both lake locations, this difference was more evident in
Lake Victoria: +227% (from 16·0% to 52·3%) for CCA and
+80% (from 16·0% to 28·8%) for SEA-ELISA. This together
with the fact that age is a factor associated with infec-
tion intensity, could be an indication that in Lake Victoria,
for example, heavier infections are much slower to accrue
than in Lake Albert reﬂecting transmission heterogeneities
between lacustrine environments which is also supported
by differences in infection intensities of the mothers.
Recent research has also identiﬁed that parasite popu-
lations between lakes are genetically distinctive, which
may have some bearing upon egg production patterns and
immuno-pathogenic proﬁles.41
4.3. PZQ and the young child
Although a relatively small sample size was used to
calculate CRs and ERRs, the results fall within the ranges
found in the existing literature with good parasitologi-
cal performance.42-45 Administration of PZQ in the young
child resulted in some putative side-effects, although
many had resolved by 24hours after treatment and even
fewer were present 21 days after treatment, evidence of
their mild and transient nature, and in accordance with
previous observations. An obvious caveat for our data
is the fact that symptoms were being reported by the
mother on behalf of the child.46 Interestingly, mothers
reported signiﬁcantly more side-effects one day after they
received treatment, particularly dizziness (percentage dif-
ference =+10%), sleepiness (+15%), fatigue (+16%), vertigo
(+14%) and cramps (+11%), than their children, possibly due
to the higher prevalence and mean intensity of S. mansoni
infections recorded in the mothers.
These results and observations on the risk of infection
in the very young child, point to the necessity of produc-
ing a PZQ syrup formulation at low cost but it should be
remembered that these formulations tend to have shorter
shelf-lives and thus pose a greater challenge for ﬁeld
logistics than tablets. In addition, using syrup requires an
entirely different dosing pole. Although time-consuming,
crushing the tablets with ﬂavoured juice is practicable,
with minimal impact on the efﬁcacy of the drug, and an
ternatio112 J.C. Sousa-Figueiredo et al. / In
extended dosing pole is now available. As an additional
future reﬁnement, PZQ tablets should be manufactured
with markings to allow easy division into four quarters
for more precise dose estimation when treating children
weighing between 7·5 and 11·25kg. Finally, administra-
tion of PZQ to young children will be made easier after the
development of more palatable PZQ tablets with the exclu-
sion of the inactive isomer that gives the drug a bitter taste,
though we have seen that many younger children do not
immediately recognise the unusual taste of PZQ.47
Twonewheight intervals havebeenadded toextend the
PZQ dose pole: 60–84 cm for one-half tablet and 84–99 cm
for three-quarters of one tablet. Additionally, as ascer-
tained using a dataset composed largely of preschool
children, the current WHO pole’s single table lower limit
was adjusted from 94cm to 99 cm.19 Our extended PZQ
dose pole was very accurate within Uganda as well as
in Zanzibar (prevalence levels of acceptable dosages esti-
mated were 98·6% and 97·6%, respectively). Although we
have demonstrated our pole would be exportable to other
communities outside of Uganda (e.g. Zanzibar, Tanzania),
we suggest the evaluation of these new divisions by other
African Ministries of Health. Additionally, further safety
and efﬁcacy tests need to be conducted before imple-
menting a formal update to the current WHO dose pole,
consequently including children less than four years of
age. In the absence of a Paediatric Investigation Plan (PIP)
or equivalent (Paediatric Research Equity Plan; PREA) for
PZQ, the international community needs to consider ways
in which drug safety could be sensibly assessed perhaps
in a manner similar as to how the inclusion of pregnant
women in mass treatment campaigns was advocated.18 It
is worth noting that interventions targeting STH infections
in preschool children are out-performing, in terms of treat-
ment coverage, school-based interventions, so if the above
steps are set in place, control of schistosomiasis in these
young children could achieve such programmatic perfor-
mance within the foreseeable future.48
5. Conclusion
We call for the immediate inclusion of preschool chil-
dren in the Ugandan national schistosomiasis control
programme and, to facilitate the administration of PZQ, our
extended dose pole can be applied. In so doing, we take a
crucial step towards addressing this issue in Uganda and
now draw attention to the present health inequity else-
where in sub-Saharan Africa.
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